This research study evaluates Xanamem®, an investigational treatment for Alzheimer’s disease. The goal is to see if it can help individuals with mild to moderate dementia.
Eligibility:
• Ages 50+
• Diagnosed with mild or moderate dementia due to Alzheimer’s
• Must have a caregiver who can attend all study visits